28 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
27 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
29 May 2025 Date | | - Cons. EPS | - EPS |
26 Nov 2024 Date | | - Cons. EPS | - EPS |
29 Aug 2024 Date | | - Cons. EPS | - EPS |
28 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
27 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
29 May 2025 Date | | - Cons. EPS | - EPS |
26 Nov 2024 Date | | - Cons. EPS | - EPS |
29 Aug 2024 Date | | - Cons. EPS | - EPS |
Medical Devices Industry | Healthcare Sector | Mr. Christopher H. Freeman CEO | TSX-V Exchange | CA5850901037 ISIN |
US Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
MedX Health Corp is a distinguished enterprise that contributes significantly to the medical field by developing, manufacturing, and marketing advanced skin-related screening tools and phototherapy devices. The company's innovative solutions cater to the vast needs of pain relief and tissue repair. Having its foundation laid in 1999 and being headquartered in Mississauga, Canada, MedX Health Corp has expanded its horizons beyond the Canadian borders, reaching out to the United States and other international markets. It leverages cutting-edge technology to facilitate the early detection of skin ailments and offers therapeutic devices that harness the power of light energy for rehabilitation purposes. Through its DermSecure telemedicine platform, it also pioneers in providing telehealth solutions that support remote patient assessment, making it a notable player in the medical technology industry.
MedX Health Corp. offers SIAscopy, a revolutionary medical device technology, designed for the scanning of skin to identify suspicious moles and lesions. This technology stands out as a critical tool in the early detection of skin cancer, enabling healthcare professionals to assess skin anomalies meticulously. Through its precise and non-invasive approach, SIAscopy represents a significant advancement in dermatological diagnostics.
The company also specializes in providing phototherapeutic medical devices, which utilize light energy in the form of lower-level laser and LED. These devices are aimed at the rehabilitation market, offering treatments for pain and tissue damage. The effectiveness of these devices in promoting tissue repair and alleviating pain underscores MedX Health Corp.’s commitment to innovative healthcare solutions.
MedX Health Corp. operates the DermSecure telemedicine platform, a web-based platform that supports the remote operation of its SIAscopy scanning technology. This platform is integral to the deployment of the company’s technology across networks of third-party locations, enabling the capture and transmission of patients' mole and lesion images alongside pertinent patient information. DermSecure connects patients with specialist physicians for remote assessments, embodying the company’s dedication to leveraging technological advancements for accessible and efficient healthcare solutions.